Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGFR | P43088 | 5/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25687478 | 1.00 | CFTR (0.40) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL25687479 | 1.00 | CFTR (0.40) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL25687518 | 0.97 | CFTR (0.40) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL25686197 | 0.97 | CFTR (0.40) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL30211296 | 0.97 | CFTR (0.40) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL30007155 | 0.91 | CFTR (0.38) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL28909119 | 0.91 | CFTR (0.38) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL25687410 | 0.91 | MAPT (0.37) | CFTRMAPTPOLB | |
| SCHEMBL23958707 | 0.90 | CFTR (0.39) | CFTRMAPTPTGFRCNR2SCN9A | |
| SCHEMBL25687310 | 0.90 | CFTR (0.39) | CFTRMAPTPTGFRCNR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| CN-115461336-A | RSV inhibiting 3-substituted quinoline and cinnoline derivatives | 爱尔兰詹森科学公司 | 2022-12-09 | — | — | CN | disclosed |
| WO-2021214136-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203004-A1 | RSV INHIBITING 3-SUBSTITUTED QUINOLINE AND CINNOLINE DERIVATIVES | ACE2, SIRT7, ACE | CFTR 508/4885MAPT 4162/4885PTGFR 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.